Procurement - Purchase of Opioid Overdose Reversal Drugs From Opioid Settlement Parties - Prohibition

HB 395 prohibits Maryland state funds from purchasing opioid overdose reversal drugs (like naloxone) from companies that settled opioid lawsuits involving their role in opioid manufacturing, sales, or distribution. It takes effect July 1, 2025, banning such purchases from these entities unless: (1) the company already agreed to provide drugs under a settlement signed before September 1, 2024, or (2) the company has a current contract for drug delivery signed before June 30, 2025. Crucially, any existing contracts under exception (2) cannot be renewed after July 1, 2025. This directly affects state agencies purchasing these drugs and opioid settlement companies.